The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Stefan Paul Moenig(Hôpital Beau-Séjour), Karl–Hermann Fuchs(Universitätsklinikum Würzburg), Claudia Pauligk(Goethe University Frankfurt), Nils Homann(Fraunhofer Project Centre Wolfsburg), Christoph Benckert(Vivantes Klinikum), Frank Mannes(University Hospital in Halle), Steffen Retter(Klinikum Ludwigsburg), Patrick Michl(Heidelberg University), Michael Pohl, Claus Röedel(University Hospital Frankfurt), Christoph Reißfelder(Technische Universität Dresden), Wolf O. Bechstein(Unknown), Jakob R. Izbicki(Universität Hamburg), Hakan Alakus(University Hospital Cologne), Alexander Novotny(Klinikum rechts der Isar), Julia Gumpp(Kliniken des Landkreises Lörrach), Hauke Lang(Johannes Gutenberg University Mainz), Mitsuru Sasako(Yodogawa Christian Hospital), Claus Bolling(Agaplesion Markus Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Daniel Mueller(University Hospital Frankfurt), Eva Horndasch(Kliniken des Landkreises Lörrach), Veit Kanngießer(Philipps University of Marburg), Michael Hohaus(Städtisches Klinikum Dresden), Harald Schmalenberg(Heidelberg University), Thomas Jungbluth(Fraunhofer Project Centre Wolfsburg), Thomas Zander(Integrated Oncology (United States)), Matthias Schwarzbach(Klinikum Frankfurt Höchst), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Arndt Vogel(Princess Margaret Cancer Centre), Christian Schölz(Vivantes Klinikum), Dietmar Lorenz(Sana Klinikum Offenbach), Winfried Padberg(Justus-Liebig-Universität Gießen), Manish A. Shah(NewYork–Presbyterian Hospital), Jorge Riera Knorrenschild(Philipps University of Marburg), Wolfgang Blau(Universitätsklinikum Gießen und Marburg), Karel Caca(Klinikum Ludwigsburg), Andreas Wünsch(Fraunhofer Institute of Optronics, System Technologies and Image Exploitation), Michael Winkler(Medizinische Hochschule Hannover), Sylvie Lorenzen(Technical University of Munich)
Cited by 226
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k